Method of production of anti-luteolytic blood - alb, method of treatment and prevention of postpartum obstetric and gynecological diseases in cows
FIELD: veterinary medicine.
SUBSTANCE: method for production of anti-luteolytic blood - AlB is that luteolisate is administered subcutaneously to gelding twice with an interval of 14 days at a dose of 20 ml each, containing parts of the corpus luteum of pregnancy of cows, and after 14 days after the second administration the blood is taken from the jugular vein. The method of treatment and prevention of persistent corpus luteum, subinvolution of uterus and postpartum endometritis in cows comprises at the background of general therapy the use of anti-luteolytic blood that is administered subcutaneously in the neck region twice at a dose of 10 ml each with an interval of 6 days.
EFFECT: use of anti-luteolytic blood promotes the resorption of the corpus luteum of pregnancy and shortens the duration of postpartum involution of genitals that enables to prevent and reduce the time of treatment of ill cows with persistent corpus luteum, subinvolution of uterus and postpartum endometritis.
The invention relates to the field of veterinary obstetrics, and can be used for the prevention and treatment of obstetric-gynecological diseases in cows.
In the reproductive system in cows after normal delivery, great changes take place. 2-3 hours after childbirth, the uterus is sawsana. The uterus becomes thick, on the surface palpation folds. Caruncula fill almost the entire lumen. Horn, who served as plodovmestylisa, more free. On days 3-5 of the lumen of the cervical canal is narrowed so that only skips 2-3 finger. Lochia in cows in the first bloody days; on days 3-5 of them in the form of thick, turbid, viscous mucus. Then the Fuckers become chocolate color; 8-th day acquire the character of mucus, and for the 10-14th day cease.
After birth the number of cells of the yellow body (Corpus luteum of pregnancy gradually begins to decrease. Vessels, richly penetrating yellow body, with a decrease in its total approach, forming a dense network. Gradually these vessels also undergo degeneration, turning into soedinitelnotkannye strands. The involution of the yellow body of pregnancy ends to the 16-th day of the postnatal period and is accompanied by intensive growth of follicles .
In optimal conditions, feeding, care, maintenance and proper use of natural postpartum who evolucia genital organs of cows ends up on average 3 weeks after birth, their ovaries are intensively developing in the egg follicles, produce estrogen (follicular hormone), and breeding may again come fertilization and pregnancy .
Because of the inadequate feeding and poor detention conditions for highly productive cows, especially in the absence of walks in the stall period, the process of involution continues until 40 days or more, these cows often there is a lack of sexual cycles (anaphrodisia)and by rectal examination found luteum in the ovaries [3, 8].
Remaining after the birth of a yellow body supports the body with a high level of progesterone. This hormone inhibits the growth of follicles and ovulation, delays postpartum involution .
D. Hammond (1955) indicates that in cows under the influence of the follicular hormone, increases the resistance of the uterus to infection and the risk of infection when the penetration of bacteria into the uterus is much smaller than in cows under the influence of hormone yellow body. He explains this by the fact that evolved under the influence of estrogen mucus creates a barrier for microbes, while eye-catching under the influence of progesterone, the uterine milk is a good medium for them. In addition, estrogenic hormones increase the protective function of the uterus by reinforced what I leukocyte reaction .
Thus, the violation of resorption of the yellow body of pregnancy in the postpartum period in cows disturbed antimicrobial and contractile function of the uterus, which contributes to the development of subinvolution of the uterus and postpartum endometritis, there is a long violation of the sexual cycles and infertility[1, 2, 3, 4, 5, 6, 7, 8].
In inflammatory processes in the uterus disrupted production of prostaglandin F2a, because what happens regression yellow body, which is delayed for a long time. Therefore, when studying cows, sick subinvolution of the uterus and postpartum endometritis, often in the ovaries detected yellow body.
Hence the main task of the modern integrated prevention subinvolution of the uterus, postpartum endometritis and persistent luteum in cows is the use of drugs for early resorption yellow body, restoring tone and contractile function, stimulation of regeneration of epithelial tissues in the uterus, increasing the overall resistance of the organism [3, 5].
The purpose of the invention is the generation and application of antisocially blood (Ala), which has therapeutic and preventive action aimed at improving the body's defenses, to accelerate the resorption of the yellow body of pregnancy and involution of the uterus in cows.
The home is jaimoe invention meets the criterion of "novelty", since the use antisocially blood (Ala) for the prevention and treatment of cows with persistent yellow body, subinvolution of the uterus, postpartum endometritis is not known.
The claimed invention meets the criterion of "significant differences", as an additional effect - profilactics postpartum obstetric-gynecologic diseases and reduces the treatment time sick cows.
To obtain antisocially blood (Ala) is a young healthy gelding, which subcutaneously injected luteolysis cows, containing parts of the yellow body of pregnancy at a dose of 20 ml, twice with an interval of 14 days. The introduction of a foreign agent promotes the formation in the body gelding biologically active substances with directed action, accelerating the absorption of the yellow body of pregnancy and involution of the uterus of cows. 14 days after the second injection of luteolata the gelding take blood from the jugular vein and add an anticoagulant.
The known method of applying prostaglandinsdanger drugs (magestrofan estrofan, dinoprost, hansaplast and others) when persistent yellow body and cysts luteum in cows, but these drugs do not have General-stimulating action. Studies have shown that therapeutic effect of magestrofana in the postpartum period yields e is the efficiency of use antisocially blood (Ala).
There is a method of using the drug KGK when persistent yellow body in cows, but it contains only gonadotropic hormones and has no purposeful action aimed at the absorption of the yellow body.
Used autohemotherapy cows with persistent yellow body - two intramuscular injections of 50-100 ml with an interval of 5 days, has only subsectimeorig effect and does not contribute to the resorption of the yellow body [3, 5].
However antisocially blood (Ala) compared with conventional Autocraft in addition to General-stimulating also has a specific action aimed at strengthening resorption yellow body of pregnancy, which accelerates postpartum involution of the genital organs. The efficiency of Ala is enhanced by the background of the use of uterotonic drugs.
Antisocially blood (Ala) is introduced to stimulate postpartum involution of the genital organs fresh cows and prevention of postpartum obstetric-gynecologic diseases (subinvolution of the uterus, postpartum endometritis, persistent yellow body) subcutaneously in the neck twice with 10 ml immediately after removal of the fetus and after 6 days.
With care to the persistent yellow body, subinvolution of the uterus, postpartum endometritis cows antisocially blood (Ala) administered subcutaneously in the neck of the double is but 10 ml, with an interval of 6 days, on the background of therapy.
Tested antisocially blood (Ala), on the background of complex treatment of sick cows with persistent yellow body, subinvolution of the uterus, postpartum endometritis (according to 5 sick animals) showed a high therapeutic efficacy.
When applying antisocially blood (Ala) from prevention to 20 fresh cows persistent yellow body, subinvolution of the uterus and postpartum endometritis they were not observed. The experimental cows were marked shortening of the period of excretion lohii and involution of the uterus.
Use antisocially blood (Ala) accelerates resorption yellow body and reduces the duration of postpartum involution of the genital organs, which allows prevent and reduce the time of treatment of cows with persistent yellow body, subinvolution of the uterus and postpartum endometritis.
Sources of information
1. Veterinary obstetrics and gynecology. Edited by Prof. Gagarinova. - L., "Kolos" (Leningrad. separa-tion), 1977. - S-361.
2. Veterinary obstetrics, gynecology and bioengineering breeding / Apostolescu, Vshield, Viamichelin andetc.; Edited Viamichelin and Megerramova. - 7th ed., revised and enlarged extra - M.: Kolos, 2000. - S-317.
3. Goncharov VP, Karpov V.A. Prevention and treatment of gynecological diseases is any cows. - 2nd ed., Rev. and supplementary): Rosagropromizdat, 1991. - 190 S.
4. Ermachenko NN. Obstetrics and gynecology farm animals. Ed. 2nd, Rev. and extra - L., "Kolos" (Leningrad. separa-tion), 1976. - S-182.
5. Sankowski IVAN Prevention and treatment of obstetric and gynecological diseases in cows. - Ufa, Bashkir publishing house, 1982. - 232 S.
6. Logvinov SHOSTAKOVICH Pregnancy and parturition in cows. - K., "Harvest", 1975, S-229.
7. Workshop on obstetrics, gynecology and bioengineering of animal reproduction./ Viamichelin, Mgerasimov, Vphone and others - M.: Colossus, 2004. - S-168.
8. Titova Century and other effects on the involution of the uterus in cows quantum method.// Titova Century, Nasibov F., Baitlesov E., Katukov Century, Vlasova,/ Dairy and beef cattle, No. 1, 2006. - P.24-25.
9. Shipilov Century Physiologically Foundation for the prevention of infertility in cows, M., 1977.-288 C.
1. The method of obtaining antisocially blood - Ala, characterized in that is used gelding, who twice with an interval of 14 days subcutaneously injected luteolysis at a dose of 20 ml, containing parts of the yellow body of pregnancy, cows, and 14 days after the second injection, blood is taken from the jugular vein.
2. Method for the treatment and prevention of persistent yellow body, subinvolution of the uterus and postpartum endometritis in cows, including on the background of therapy application antisocially blood - Ala, great for the present, however, that as a drug used antisocially blood - Ala, which is injected subcutaneously in the neck twice 10 ml with an interval of 6 days.
SUBSTANCE: haemostatic values, endothelial dysfunction characteristics, diagnosed genetic forms of thrombophilia and habitual miscarriage are detected; the detected disorders are assessed in points depending on the gestational age. That is followed by calculating the total score, and therapy is prescribed depending on the total score. The case follow-up involves changing the therapeutic regimen with the total score variations.
EFFECT: method enables assessing objectively and standardising the therapeutic options in thrombophilic disorders accompanying pregnancy.
1 tbl, 2 ex
FIELD: veterinary medicine.
SUBSTANCE: aminoseleton is administered subcutaneously to animals in combination with symptomatic preparations - magestrofan, uteroton, tetragidrovit and etiotropic preparation. As etiotropic preparation the combination antimicrobial agent is used containing cefotaxime, neomycin, prednisolone, emulsifier, monoglyceride, vaseline oil, in the following ratio of components, wt %: cefotaxime - 7.0%, neomycin - 1.0%, prednisolone - 0.2%, emulsifier - 3.0%, monoglyceride - 1.0%, vaseline oil to 100.0, which is administered intrauterine 2-3 times with the 24-hour intervals in a dose of 20 ml.
EFFECT: invention improves therapeutic efficacy in chronic and latent endometritis.
3 tbl, 3 ex
SUBSTANCE: agent for mastitis prevention comprises glycerine and distilled water and as antimicrobial agent it comprises 20% anavidin solution, with the following component ratio, wt %: 20% anavidin 1.5-2.5; glycerine 7.5; distilled water to 100.0. The agent forms on the teats the solid transparent polymeric antimicrobial film after application, preventing the penetration to the teat canal of pathogenic microflora, and also facilitates softening of the teat skin.
EFFECT: agent is easy to produce and apply, treatment with the claimed agent prevents effectively mastitis in lactating cows.
1 tbl, 2 ex
SUBSTANCE: invention relates to medicine, namely to gynaecology, reflexotherapy and pelotherapy. A method includes carrying out a course of antibacterial and/or antiviral therapy, which is started on 5-7 day of a menstrual cycle. From 5-7 day of the following menstrual cycle a course of pharmacopuncture is performed by introduction of homeopathic preparations into acupuncture points (AP). On 1, 3, 5, 7, 9, 11 and 13 days of the course Traumel C is introduced into points E36 (2), V31 (2), V32 (2), V33 (2), V34 (2). On 2, 4, 6, 8, 10, 12, 14 days of the course Ovarium compositum is introduced in AP Rp6 (2). Simultaneously with the course of pharmacopuncture or starting from 5-7 day of the following menstrual cycle a course of pelotherapy is carried out. Introduction of gel, based on the Dead Sea mud, is performed rectally for 30 minutes, 1 time per day.
EFFECT: method ensures recovery of the two-phase menstrual cycle due to normalisation of endometrium and vagina biocenosis, improvement of local immune and vegetative status, increases duration of remission.
4 cl, 2 ex
SUBSTANCE: group of inventions refers to veterinary science and is applicable for treating mastitis in cows. The declared agent contains veterinary Vivaton - 10%, ASD-2 - 4%, Bursanatal - 6% and 0.9% normal saline up to 100%. The method involves administering the declared agent with underlying general strengthening and stimulating therapy. The agent is intra-cisternal into an involved one-quarter of a dug in a dose of 5 ml daily once a day using a syringe in number of 3-5 procedures.
EFFECT: using the declared group of invention enables providing higher efficacy in treating mastitis in cows.
2 cl, 7 tbl, 1 ex
SUBSTANCE: invention relates to the field of veterinary and is intended for activation of reproductive function in Karakul sheep. A biological preparation, including a female placenta extract and vitamins, is characterised by the fact that it additionally contains phytoextracts (in which a physiological solution is used as an extractant) of seeds of desert forage plants - annual Salsola: Salsola sclerantha C.A.M, Gamanthus gamocarpus Mog, Climacoptera lanata Pall., and phytoextracts (in which the physiological solution is used as the extractant): of rhizomes of Sweet flag (Acorus calamus L.) and caper (Capparis spinosa L.) in a ratio placenta extract: phytoextracts as 1:2 and a water-soluble vitamin-amino acid complex "Chiktonic", with the following component ratio, ml: an extract of female placenta 100, a phytoextract of seeds of Salsola sclerantha C.A.M. 30, a phytoextract of seeds of GamanthusgamocarpusMog 40, a phytoextract of seeds of Climacoptera lanata Pall. 40, a phytoextract of rhizomes of Sweet flag (Acorus calamus L.) 40, a phytoextract of seeds of caper (Capparis spinosa L.) 50, the water-soluble vitamin-amino acid complex "Chiktonic" 2.
EFFECT: application of the claimed preparation contributes to activation and normalisation of reproductive function in sheep, increases synchronicity of passing ewes in the state of readiness and fertility.
3 tbl, 1 ex
FIELD: veterinary medicine.
SUBSTANCE: method comprises intracisternal administration of masticef at a dose of 5 ml with 24-hour intervals 2-4 times. The biogenic stimulator is used as a preparation obtained from pig spleen (BSS) by ultrasonic homogenisation, heating the homogenate, and its cooling, supernatant precipitation followed by removal of ballast proteins by centrifugation or ultrafiltration. The biogenic stimulator is administered subcutaneously in the upper third part of the neck in 1-3-5-7 days of treatment at a dose of 30-35-40-45 ml, respectively.
EFFECT: method enables to increase the effectiveness of treatment of all forms of mastitis in cows, to the reduce treatment time, and to reduce the term of milk rejection.
4 tbl, 3 ex
FIELD: chemistry, pharmacology.
SUBSTANCE: biologically active composition for improving sexual function in men includes powder of antlers of Maral, or Manchurian wapiti, or sika deer, and additionally contains powder of leaves or rhizomes with roots of Rhaponticum carthamoides, taken in specified ratio (version).
EFFECT: composition makes it possible to extend spectrum of highly efficient preparations for improvement of sexual function in men with minimal quantitative content of highly effective components from plant and animal raw material, demonstrating action synergism as components of composition.
4 cl, 6 tbl, 2 ex
FIELD: veterinary medicine.
SUBSTANCE: against the background of lymphotropic injections of enzaprost F (prostaglandin F2α) and antibiotic in half-daily doses a course of lymph-stimulating injections is carried out in the subcutaneous tissue in the projection of the inguinal rings, which is administration into the interspinous ligament thickness of the spine at the level of L2-L6 of 1 ml per 5 kg of animal weight of mixture consisting of 32 IU lydase, 500 thousand IU roncoleukin, 0.1 ml butomidore, 4 ml of 2% lidocaine solution, and 5 ml of 40% glucose solution.
EFFECT: method enables to increase the effectiveness of therapy while reducing the probability of development of side effects and relapses of disease by increasing the drainage function of the lymphatic system, acceleration of lymph flow and processes of neogenesis while reducing the duration of treatment and reduction of daily doses.
SUBSTANCE: blood is examined for angiogenic factors, namely soluble fms-like tyrosine kinase (sFlt-1) and placental growth factor (PIGF). An angiogenic factor (Ka) is calculated by formula: Ka=sFlt-1/PlGF×10. If Ka is 10 or less, the pregnant woman is stated to require no admission to hospital, no case follow-up; doctor's appointments are scheduled. If Ka falls within the range of 10 to 50, the pregnant woman is admitted to hospital, wherein foetal monitoring, Doppler monitoring are performed; an amniotic fluid index (AFI) is calculated; a therapy aiming at the uterine-placental blood flow improvement is prescribed for 10 days. The amount of infusion makes 400 ml a day. The prescribed preparations are Actovegin, Trental, Instenon, Carnitini chloridum. Control ultrasonography, Doppler monitoring, foetal monitoring, AFI and Ka measurements are performed 2 weeks later. The pregnant woman is discharged from hospital if observing no negative trends. If Ka falls within the range of 50 to 100, the pregnant woman is admitted to hospital, wherein foetal monitoring, Doppler monitoring are performed, and AFI is measured; a therapy aiming at the uterine-placental blood flow improvement is prescribed for 14 days The amount of infusion makes 800 ml a day. The prescribed preparations are Actovegin, Trental, Instenon, Carnitini chloridum. Control Doppler monitoring and foetal monitoring are performed every 3 days; 2 weeks later control Ka is measured. If the trend is positive, the pregnant woman may be discharged from hospital, while no positive trend requires another 2 weeks of the therapy. If Ka is 100 or more, but less than 150, the pregnant woman is admitted to hospital, wherein foetal monitoring, Doppler monitoring are performed, and AFI is measured; a therapy aiming at the uterine-placental blood flow improvement is prescribed for 14 days. The amount of infusion makes not less than 800 ml a day with the same preparations prescribed. Those are added with the preparations for homeostasis correction, including Fraxiparine, Fragmin, Clexane optionally. Control Doppler monitoring and foetal monitoring are daily. Hypamnion also requires measuring control AFI. If a gestational age is less than 34 weeks, respiratory distress syndrome (RDS) should be prevented by administering the preparation Dexon 24 mg according to the schedule: 6 mg every 12 hours 4 times. Control Ka is necessarily measured after 2 weeks of the treatment. If the trend is positive, the pregnant woman may be discharged from hospital, while no positive trend requires another 2 weeks of the therapy. If Ka is 150 or more, and the gestational age is more than 34 weeks, the therapeutic approach is the same, as for Ka being within 100 to 150, control Doppler monitoring, foetal monitoring are performed twice a day, as well as measuring AFI. If observing no foetal weight gain for 2 weeks of the therapy or the functional state of the foetus deteriorates, a Cesarean section is performed. If the gestational age is 34-36 weeks, the therapeutic approach and follow-up are the same as for the gestational age of 34 weeks, except for the prevention of foetal RDS. However, if observing the deterioration of a foetal movement pattern or the functional status of the foetus, a Cesarean section is performed according to the foetal monitoring and Doppler monitoring findings. If the gestational age is more than 36 weeks, and Ka is 150 or more, pre-mature delivery is applied.
EFFECT: optimal selection of the therapeutic approach ensured by determining the values reflecting the severity of the cardiovascular disorder directly in the uterine-placental complex and mother's and foetus's compensatory capacities.
FIELD: medicine, pharmaceutics.
SUBSTANCE: present group of inventions refers to medicine, namely to therapy and pharmacology, and can be used to increase pharmacological activity and therapeutic efficacy of drug preparations of activated-potentiated forms of hyperdiluted antibodies. That is ensured by administering a pharmaceutical composition containing activated potentiated pathogenic antigen and endothelial NO-synthase antibodies.
EFFECT: administering this composition provides higher therapeutic efficacy ensured by a synergetic effect of the ingredients of the composition.
10 cl, 18 ex
SUBSTANCE: invention refers to medicine and veterinary science and concerns a method for producing the purified antigen of Dirofilaria immitis. The presented method involves mechanical homogenisation, centrifugation of a homogenate, collection of a supernatant to be used as an antigen; the homogenisation involves a 2-cm head end of a mature female of Dirofilaria immitis placed in an aqueous solution of saccharose 0.25 M in a ratio of 1:3, frozen at a temperature of -18°C, that is followed by mechanical homogenisation and protein extraction in the aqueous solution of saccharose 0.25 M at 4°C for 12 hours, wherein 3 cycles of five 30-second ultrasonic homogenisations of the supernatant is performed at 70 kHz every 30 seconds at 0°C; the supernatant prepared after ultrasonic homogenisation is dissolved in cooled acetone at a temperature of 0°C in a ratio of 1:20 with exposition for 1 hour at a temperature of 4°C.
EFFECT: presented invention enables producing the high-sensitivity and specificity antigen and can be used in diagnosis of dirofilariasis in humans and animals.
2 tbl, 1 ex
SUBSTANCE: invention relates to medicine and deals with an application of an antibody, which binds with residues of 1-5 or 3-7 A-beta, to reduce vascular amyloid in a patient with cerebral amyloid angiopathy, with the antibody being introduced intravenously or subcutaneously.
EFFECT: invention provides purification of the patient's vessels from amyloid deposits.
9 cl, 2 ex, 6 dwg
SUBSTANCE: strain Moraxella bovoculi has antigenic, virulent properties and immunogenic activity. It is deposited under the number "SH-Ch6 N-DEP" in the All-Russian State Collection of strains of microorganisms used in veterinary medicine and animal husbandry FSBI "Russian national centre of quality and standardisation of drugs for animals and feed". The strain can be used in manufacture of diagnostic preparations and vaccines against infectious keratoconjunctivitis of cattle.
EFFECT: invention enables to produce diagnostic preparations and vaccines against infectious keratoconjunctivitis of cattle.
1 tbl, 3 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine and veterinary science.
EFFECT: using RPE (ribosomal protein extract) together with Th1-activating adjuvant for preparing a drug for treating or preventing a parasitic disease provides cross-protective immunity against different Leishmania species.
13 cl, 7 dwg
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, namely to therapy, and concerns treating viral infections. That is ensured by administering a drug containing active ingredients presented by an activated-potentiated form of human gamma-interferon antibodies and an activated-potentiated form of CD4 receptor antibodies.
EFFECT: administering this combined drug provides effective treatment of viral diseases ensured by the synergetic antiviral effect of the active ingredients of the drug.
10 cl, 6 tbl, 5 ex
SUBSTANCE: invention relates to a method of obtaining a preparation, stimulating antigen-independent differentiation of B-lymphocytes, from a raw material of an animal origin. The method of obtaining the preparation, stimulating antigen-independent differentiation of B-lymphocytes, from the raw material of the animal origin includes homogenisation of the preliminarily frozen at -40°C tissue of porcine endometrium with further extraction for 36 hours in 3% solution of acetic acid with a ratio 1 part of the raw material to 5 parts of an acetic acid solution and addition of zinc chloride in dose 1 g per 1 l of 3% acetic acid at pH 3.5-4.0, in which the obtained extract is filtered, centrifuged at 3000 rev/min for 20 min, a supernatant liquid is poured into the cooled acetone with a ratio 1:5, a sediment is formed for 12 hours at -4°C, precipitated with acetone, the target product is additionally purified by ultrafiltration with the limit of molecular retention 5kD, with further filtration and lyophilisation.
EFFECT: extension of the assortment of highly efficient medications, stimulating antigen-independent differentiation of B-lymphocytes.
5 tbl, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions discloses a pharmaceutical composition and a kit containing type II anti-CD20 antibodies and a proteasome inhibitor applicable in treating cancer expressing CD20. Also, the group of inventions refers to using type II anti-CD20 antibodies for obtaining a drug preparation applicable for treating cancer expressing CD20 in a combination with the proteasome inhibitor.
EFFECT: group of inventions is characterised by using the antibodies possessing high antibody-dependent cell-mediated cytotoxicity and efficacy in the therapy of cancer diseases.
13 cl, 3 dwg, 4 tbl, 3 ex
SUBSTANCE: invention refers to immunology, medicine and biotechnology. What is presented is a method for stimulating a specific anti-tumour immune response to breast cancer cells with the use of dendritic cells transfected by polyepitope DNA construct. The cells recovered from the peripheral blood of relatively healthy donors, transfected by the polyepitope structure are cultured with a non-adherent fraction of mononuclear cells.
EFFECT: method enables providing higher effectiveness and cost effectiveness of preparing cytotoxic lymphocytes.
SUBSTANCE: invention relates to biotechnology. The method of treating or preventing a PCV2 infection or reducing clinical symptoms caused by or associated with a PCV2 infection in animals, having anti-PCV2 antibodies, involves single-step administering of an effective amount of a PCV2 antigen to the animal in need of such treatment or preventive treatment.
EFFECT: use of the disclosed method prevents adverse interaction of maternal anti-PCV2 antibodies with the PCV2 antigen, thereby becoming real vaccination or treatment for animals aged up to 3 weeks.
18 cl, 3 dwg, 5 tbl, 4 ex
SUBSTANCE: method involves intravenous allogeneic transplantation of multipotent mesenchymal stromal cells recovered from the placenta in an amount of 6 mln cells/kg. Additionally, haemopoietic stem cells recovered from umbilical blood in an amount of 300 thousand cells/kg are introduced.
EFFECT: method enables reducing the number of cytogenetically changed cells, promotes activating myeloid tissue regeneration in old laboratory animals.
4 tbl, 1 ex